Incidence and Management of Proteinuria in the IMbrave150 Clinical Trial
This article responds to your request for information on Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) and the incidence and management of proteinuria in the IMbrave150 clinical trial.
Last updated September 15, 2023
Summary
- Proteinuria is a common adverse event associated with Avastin.
- At trial enrolment, patients were tested for pre-existing proteinuria.
- Avastin management guidance was provided in the study protocol.
- The incidence of all grade proteinuria during the study was 30%.
- Patients could still continue single-agent therapy with Tecentriq if they discontinued Avastin due to proteinuria.
IMbrave 150 Study design
IMbrave150 was a Phase III, open-label, randomised study of Tecentriq in combination with Avastin compared with sorafenib, in patients with unresectable or advanced hepatocellular carcinoma (HCC) who had not received prior systemic therapy.[1]
Inclusion criteria related to proteinuria
Within 7 days prior to IMbrave150 trial initiation, patients underwent dipstick urinalysis for proteinuria. Table 1 shows the recruitment criteria.[2]
Table 1: Proteinuria analysis at IMbrave150 initiation
Incidence of proteinuria in IMbrave150
Table 2 shows the incidence of proteinuria in the IMbrave150 trial. In clinical trials investigating Tecentriq in combination with different therapies in different indications, all grade proteinuria arose at an of incidence of 8.2%.[3] In clinical trials studying Avastin in different indications, proteinuria arose within a range of 0.7% to 54.7% of patients receiving Avastin.[4] In these trials proteinuria ranged in severity from clinically asymptomatic, transient, trace proteinuria to nephrotic syndrome.[3,4]
Table 2. Incidence of all-cause proteinuria during IMbrave150 in safety-evaluable population [5]
Abbreviations: IV=intravenous; Q3W=every 3 weeks; bid=twice a day; Data Cutoff: Aug 31st 2020
Management of proteinuria in IMbrave150
Proteinuria was managed in the IMbrave150 trial as per Table 3.
Table 3. Management guidelines for proteinuria associated with Avastin [5]
Avastin discontinuation as a result of proteinuria
The protocol of the IMbrave150 study allowed patients who discontinued either Tecentriq or Avastin due to adverse event to continue on single-agent therapy, until loss of clinical benefit or unacceptable toxicity associated with the single agent.[5] Table 4 shows the incidence of Avastin treatment interruptions and withdrawals due to proteinuria.
Table 4: Avastin treatment interruptions/dose modifications and withdrawals due to proteinuria [6]
Abbreviations: IV=intravenous; Q3W=every 3 weeks; bid=twice a day, Data Cutoff: Feb 2023
Additional information
For further information related to Avastin-related proteinuria, please refer to the article "Monitoring and Management of Avastin-Associated Proteinuria".
References
- Finn R, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020;382:1894-1905. https://www.ncbi.nlm.nih.gov/pubmed/32402160
- Protocol for: Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905. DOI: 10.1056/NEJMoa1915745. Available at https://www.nejm.org/doi/suppl/10.1056/NEJMoa1915745/suppl_file/nejmoa1915745_protocol.pdf.
- Roche Internal Regulatory Document, accessed on 03-Jul-2023.
- Roche Internal Regulatory Document, accessed on 03-Jul-2023.
- Cheng A, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. See supplementary data " Multimedia component 4" for protocol and safety data. J Hepatol 2022;76:862-873. https://www.ncbi.nlm.nih.gov/pubmed/34902530
- Roche Clinical Study Report, accessed on 14-Sept-2023.
Medinfo
Need to contact Roche?
Request Product Information
Request Product Information
Ask us a question and request information about Roche products or services.
Report a potential side effect
Report a potential side effect
If you have experienced potential side effects with a Roche product you can report it here.
Report a potential product defect
Report a potential product defect
If you suspect a potential defect or a Roche product has not met your expectations you can report it here.
Request temperature stability assessment
Request temperature stability assessment
Request an assessment if your product was stored outside the recommended temperature range.